Two Sigma Investments LP bought a new position in shares of Strongbridge Biopharma plc (NASDAQ:SBBP) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 78,047 shares of the biotechnology company’s stock, valued at approximately $148,000.
A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. Barclays PLC boosted its position in Strongbridge Biopharma by 91.5% in the 4th quarter. Barclays PLC now owns 37,077 shares of the biotechnology company’s stock worth $77,000 after purchasing an additional 17,718 shares in the last quarter. State Street Corp boosted its holdings in Strongbridge Biopharma by 6.5% during the fourth quarter. State Street Corp now owns 676,371 shares of the biotechnology company’s stock worth $1,414,000 after buying an additional 41,284 shares in the last quarter. Goldman Sachs Group Inc. grew its position in Strongbridge Biopharma by 16.4% during the fourth quarter. Goldman Sachs Group Inc. now owns 34,240 shares of the biotechnology company’s stock valued at $71,000 after buying an additional 4,814 shares during the period. BlackRock Inc. increased its holdings in Strongbridge Biopharma by 3.9% in the first quarter. BlackRock Inc. now owns 2,060,982 shares of the biotechnology company’s stock valued at $3,895,000 after buying an additional 76,865 shares in the last quarter. Finally, Acadian Asset Management LLC increased its holdings in Strongbridge Biopharma by 336.9% in the fourth quarter. Acadian Asset Management LLC now owns 48,849 shares of the biotechnology company’s stock valued at $101,000 after buying an additional 37,669 shares in the last quarter. Institutional investors own 47.56% of the company’s stock.
A number of research firms have recently commented on SBBP. Oppenheimer restated a “buy” rating and set a $6.00 target price on shares of Strongbridge Biopharma in a research report on Wednesday, May 6th. Craig Hallum initiated coverage on Strongbridge Biopharma in a report on Tuesday, March 3rd. They issued a “buy” rating and a $7.50 price objective on the stock. Finally, Zacks Investment Research downgraded Strongbridge Biopharma from a “hold” rating to a “sell” rating in a research note on Saturday. One analyst has rated the stock with a sell rating and six have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $8.65.
Strongbridge Biopharma (NASDAQ:SBBP) last announced its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported ($0.19) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.03. Strongbridge Biopharma had a negative return on equity of 57.46% and a negative net margin of 181.82%. The company had revenue of $6.67 million for the quarter, compared to analyst estimates of $5.97 million. Research analysts forecast that Strongbridge Biopharma plc will post -0.93 EPS for the current fiscal year.
Strongbridge Biopharma Profile
Strongbridge Biopharma plc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs. The company's commercial products include Keveyis, an oral carbonic anhydrase inhibitor for treating hyperkalemic, hypokalemic, and related variants of primary periodic paralysis in the United States; and Macrilen, an oral growth hormone secretagogue receptor agonist for use in the diagnosis of patients with adult growth hormone deficiency.
See Also: Do stock splits help investors?
Want to see what other hedge funds are holding SBBP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Strongbridge Biopharma plc (NASDAQ:SBBP).
Receive News & Ratings for Strongbridge Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Strongbridge Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.